Prof Joy Ho speaks to ecancer about treating relapsed multiple myeloma outside of the use of T-cell redirection therapies.

Anti-CD38 antibodies play a vital role in treatment, especially when combined with drugs like proteasome inhibitors and pomalidomide.

Many patients become refractory to lenalidomide, prompting the exploration of new options such as BCMA antibody-drug conjugates and T-cell redirected therapies.

Common side effects include cytopenias and infections, with careful monitoring required for drugs like belantamab.

Autologous transplants remain standard, but new therapies are changing treatment approaches.